Biotech

All Articles

Atea's COVID antiviral falls short to stop hospital stays in phase 3

.Atea Pharmaceuticals' antiviral has actually neglected one more COVID-19 trial, yet the biotech sti...

Neurocrine's offer to save schizophrenia possibility stops working

.Neurocrine Biosciences' schizophrenia system pivot has failed. The biotech was not able to reproduc...

Sanofi pays $110M upfront for late-stage radioligand therapy

.Sanofi has actually made an overdue entry to the radioligand party, paying 100 million euros ($ 110...

F 2G brings up $100M for 2nd attempt to receive new antifungal to market

.After F2G's initial effort to get a new class of antifungal to market was hindered by the FDA, the ...

Moderna targets $1.1 B in R&ampD spending slices, falls 5 courses in the middle of earnings tensions

.Moderna has promised to reduce R&ampD investing by $1.1 billion through 2027. The selection to shri...

Sanofi's $80M bet on Pivot dystrophy medicine ends in stage 3 fail

.Only four months after Sanofi bet $80 thousand in ahead of time cash on Key Therapeutics' losmapimo...

Oncternal equity drains 60% amidst discharges, trial firings

.Cancer company Oncternal Therapeutics is folding all its own scientific trials and also laying off ...

Roche is actually holding out hopes that its injectable being overweight possibility could inevitably show 25% fat burning in late-stage test

.Roche is actually storing out chances that its injectable weight problems possibility might inevita...

Novo Nordisk barrages 'outstanding' fat burning result for dual-acting dental medication in very early test

.Novo Nordisk has actually lifted the lid on a phase 1 test of its oral amylin as well as GLP-1 rece...

AbbVie sues BeiGene over blood cancer cells medicine proprietary knowledge

.Simply a few brief weeks after winning an FDA Fast Track tag for its investigational BTK degrader i...